Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion / Tanja Veselinović en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 214-220 Título : Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion Tipo de documento: texto impreso Autores: Tanja Veselinović, Autor ; Holger Schorn, Autor ; Ingo B. Vernaleken, Autor Fecha de publicación: 2022 Artículo en la página: pp. 214-220 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Prolactina, Hiperprolactinemia, Antipsicóticos, Reserpina, Aripiprazol Resumen: Antipsychotics are the most common cause of pharmacologically induced hyperprolactinemia. Although this adverse effect was the subject of numerous observations, the mechanisms and promotive factors were not completely investigated yet. Increased awareness of clinical consequences of hyperprolactinemia implicates the necessity for further examinations. Link: ./index.php?lvl=notice_display&id=29399 [artículo] Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion [texto impreso] / Tanja Veselinović, Autor ; Holger Schorn, Autor ; Ingo B. Vernaleken, Autor . - 2022 . - pp. 214-220. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 214-220 Palabras clave: Prolactina, Hiperprolactinemia, Antipsicóticos, Reserpina, Aripiprazol Resumen: Antipsychotics are the most common cause of pharmacologically induced hyperprolactinemia. Although this adverse effect was the subject of numerous observations, the mechanisms and promotive factors were not completely investigated yet. Increased awareness of clinical consequences of hyperprolactinemia implicates the necessity for further examinations. Link: ./index.php?lvl=notice_display&id=29399

Striatal and extrastriatal d2/d3-receptor-binding properties of ziprasidone / Ingo B. Vernaleken en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 608-617 Título : Striatal and extrastriatal d2/d3-receptor-binding properties of ziprasidone : A positron emission tomography study with [18F]fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone) Tipo de documento: texto impreso Autores: Ingo B. Vernaleken, Autor ; Christine Fellows, Autor ; Hildegard Janouschek, Autor Fecha de publicación: 2023 Artículo en la página: pp. 608-617 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agentes antipsicóticos, Relación Dosis-Respuesta, Piperazinas, Radiofármacos, Receptores de Dopamina D2, Esquizofrenia. Resumen: To elucidate the "atypicality" of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. [18F]fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Link: ./index.php?lvl=notice_display&id=30818 [artículo] Striatal and extrastriatal d2/d3-receptor-binding properties of ziprasidone : A positron emission tomography study with [18F]fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone) [texto impreso] / Ingo B. Vernaleken, Autor ; Christine Fellows, Autor ; Hildegard Janouschek, Autor . - 2023 . - pp. 608-617. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 6 (Diciembre) . - pp. 608-617 Palabras clave: Agentes antipsicóticos, Relación Dosis-Respuesta, Piperazinas, Radiofármacos, Receptores de Dopamina D2, Esquizofrenia. Resumen: To elucidate the "atypicality" of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. [18F]fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Link: ./index.php?lvl=notice_display&id=30818

---

1 (1 - 2 / 2)